QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:ACAD

ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price & News

$21.53
-4.05 (-15.83%)
(As of 09/28/2023 ET)
Compare
Today's Range
$21.16
$25.18
50-Day Range
$23.29
$31.26
52-Week Range
$13.73
$33.99
Volume
6.98 million shs
Average Volume
1.58 million shs
Market Capitalization
$3.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.81

ACADIA Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
47.8% Upside
$31.81 Price Target
Short Interest
Bearish
6.54% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of ACADIA Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$3.76 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.41) to $0.52 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

251st out of 969 stocks

Pharmaceutical Preparations Industry

96th out of 455 stocks


ACAD stock logo

About ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.

ACAD Price History

ACAD Stock News Headlines

His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
ACAD - ACADIA Pharmaceuticals Inc.
Dry Eye Syndrome Global Market Report 2023
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
H.C. Wainwright upgrades Fulcrum Therapeutics (FULC) to a Buy
Here's Why Acadia (ACAD) Looks Ripe for Bottom Fishing
Syros Pharmaceuticals (SYRS) Gets a Buy from JMP Securities
See More Headlines
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Company Calendar

Last Earnings
8/02/2023
Today
9/28/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACAD
Employees
540
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$31.81
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+44.7%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$-215,980,000.00
Pretax Margin
-19.22%

Debt

Sales & Book Value

Annual Sales
$517.23 million
Book Value
$2.47 per share

Miscellaneous

Free Float
118,704,000
Market Cap
$3.60 billion
Optionable
Optionable
Beta
0.57
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Stephen R. Davis J.D. (Age 62)
    Pres, CEO & Director
    Comp: $1.46M
  • Mr. Mark C. Schneyer (Age 49)
    Exec. VP & CFO
    Comp: $701.03k
  • Mr. Brendan P. TeehanMr. Brendan P. Teehan (Age 54)
    Exec. VP, COO & Head of Commercial
    Comp: $724.31k
  • Mr. Austin D. KimMr. Austin D. Kim (Age 59)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $722.15k
  • Mr. James K. KiharaMr. James K. Kihara (Age 42)
    VP, Chief Accounting Officer & Corp. Controller
  • Mr. Bob Mischler
    Sr. VP of Strategy & Technology Operations
  • Mr. Mark C. Johnson
    VP of Investor Relations
  • Ms. Julie Fisher
    Sr. VP of Marketing & Commercial Strategy
  • Ms. Holly Valdiviez
    Sr. VP & Head of Sales
  • Mr. Rob Ackles
    Sr. VP & Chief People Officer













ACAD Stock - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View ACAD analyst ratings
or view top-rated stocks.

What is ACADIA Pharmaceuticals' stock price forecast for 2023?

13 Wall Street research analysts have issued twelve-month price targets for ACADIA Pharmaceuticals' shares. Their ACAD share price forecasts range from $12.00 to $95.00. On average, they anticipate the company's share price to reach $31.81 in the next year. This suggests a possible upside of 44.7% from the stock's current price.
View analysts price targets for ACAD
or view top-rated stocks among Wall Street analysts.

How have ACAD shares performed in 2023?

ACADIA Pharmaceuticals' stock was trading at $15.92 on January 1st, 2023. Since then, ACAD stock has increased by 38.1% and is now trading at $21.99.
View the best growth stocks for 2023 here
.

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 10,700,000 shares, an increase of 5.1% from the August 31st total of 10,180,000 shares. Based on an average trading volume of 1,620,000 shares, the short-interest ratio is presently 6.6 days.
View ACADIA Pharmaceuticals' Short Interest
.

When is ACADIA Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ACAD earnings forecast
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.13. The biopharmaceutical company earned $165.20 million during the quarter, compared to analyst estimates of $163.86 million. ACADIA Pharmaceuticals had a negative net margin of 20.11% and a negative trailing twelve-month return on equity of 27.77%. The company's quarterly revenue was up 22.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.21) EPS.

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.13%), State Street Corp (3.31%), Geode Capital Management LLC (1.52%), Goldman Sachs Group Inc. (0.78%), Jupiter Asset Management Ltd. (0.78%) and Northern Trust Corp (0.71%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends
.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $21.99.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $3.60 billion and generates $517.23 million in revenue each year. The biopharmaceutical company earns $-215,980,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

The company employs 540 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872.

This page (NASDAQ:ACAD) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -